Takahiro Ando

Takahiro Ando

Auto-generated profile, based on publicly available information

Takahiro Ando

Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Chest
Verified
Journal Article
Closed access
TATakahiro Ando
Takahiro Ando
MKMasahiro Kawashima
Masahiro Kawashima
KMKimihiko Masuda
Kimihiko Masuda
KTKeita Takeda
Keita Takeda
KOKenichi Okuda
Kenichi Okuda
KOKen Ohta
Ken Ohta

1 March 2023 in Respiratory Investigation
Verified
Journal Article
Closed access
NANobuyasu Awano
Nobuyasu Awano
HUHirokazu Urushiyama
Hirokazu Urushiyama
HYHayato Yamana
Hayato Yamana
AYAkira Yokoyama
Akira Yokoyama
TATakahiro Ando
Takahiro Ando
TJTaisuke Jo
Taisuke Jo

4 October 2018 in Respiration
Verified
Journal Article
Open access
PDF file
TATakahiro Ando
Takahiro Ando
MKMasahiro Kawashima
Masahiro Kawashima
HMHirotoshi Matsui
Hirotoshi Matsui
KTKeita Takeda
Keita Takeda
RSRyota Sato
Ryota Sato
KOKen Ohta
Ken Ohta
Background: While nontuberculous mycobacterial (NTM) pleuritis rarely complicates pulmonary NTM infection, high mortality has been reported in case reports and small studies. Objectives: The purpose of this study was to clarify the clinical features and treatment outcomes of pulmonary NTM infection cases accompanied by NTM pleuritis. Methods: Medical records of 1,044 patients with pulmonary NTM disease were retrospectively reviewed to select patients complicated by NTM-proven pleuritis. We investigated clinical characteristics, pathogens, pleural effusion examinations, radiographic findings, treatments, and clinical course of the NTM pleuritis patients. Results: Among 1,044 cases with pulmonary NTM, NTM pleuritis occurred in 15 cases (1.4%). The mean age was 69 years with a performance status of mostly 2 or better (80.0%), and 6 cases (40.0%) were complicated by pneumothorax. Subpleural cavities were radiologically detected in 11 cases (73.3%), and extrapulmonary air-fluid level was detected in 14 cases (93.3%). Eleven patients were treated with combinations of 2–4 antimycobacterial drugs, including clarithromycin, and 2 patients were treated with isoniazid, rifampicin, and ethambutol. Chest tube drainage was performed in 11 cases, and surgical approach was added in 6 cases. The pleural effusion of 2 patients treated with only antimycobacterial medications gradually deteriorated. Two patients died from NTM pleuritis, and 1 patient died from pneumonitis during a mean of 1.8 years of follow-up. Conclusions: Comorbid NTM pleuritis was difficult to treat by medical therapy alone and resulted in a poor prognosis. In addition to antimycobacterial agents, chest tube drainage and surgical procedures in the early stages should be considered to treat NTM pleuritis.

1 May 2019 in Respiratory Investigation
Verified
Journal Article
Closed access
TATakahiro Ando
Takahiro Ando
MKMasahiro Kawashima
Masahiro Kawashima
KMKimihiko Masuda
Kimihiko Masuda
KTKeita Takeda
Keita Takeda
KOKenichi Okuda
Kenichi Okuda
KOKen Ohta
Ken Ohta

2 December 2020 in Respiration
Verified
Journal Article
Closed access
PDF file
KTKeita Takeda
Keita Takeda
MKMasahiro Kawashima
Masahiro Kawashima
KMKimihiko Masuda
Kimihiko Masuda
YKYuya Kimura
Yuya Kimura
SYShota Yamamoto
Shota Yamamoto
HMHirotoshi Matsui
Hirotoshi Matsui
Background: There is no study on the predictive factors of recurrent haemoptysis after bronchial artery embolization (BAE) with the long-term outcomes in patients with bronchiectasis (BE). Objectives: To evaluate the long-term outcomes of BAE in BE patients without accompanying refractory active infection of mycobacteriosis and aspergillosis with analysis for the predictive factors of recurrent haemoptysis. Methods: Data of 106 patients with BE who underwent BAE using coils between January 2011 and December 2018 were retrospectively reviewed. The cumulative haemoptysis control rate was estimated using Kaplan-Meier methods with log-rank tests to analyze differences in recurrence-free rate between groups based on technical success and failure, bacterial colonization status, number of BE lesions, and vessels embolized to bronchial arteries (BAs) or BAs + non-bronchial systemic arteries (NBSAs). Results: Bacterial colonization was detected in approximately 60% of patients. Computed tomography showed bronchiectatic lesions with 2.9 ± 1.4 lobes. In the first series of BAE, embolization was performed in the BAs alone and BAs + NBSAs in 65.1 and 34.9% of patients, respectively, with 2.4 ± 1.4 embolized vessels in total. The median follow-up period was 1,000 (7–2,790) days. The cumulative haemoptysis control rates were 91.3, 84.2, 81.5, and 78.9% at 1, 2, 3, and 5 years, respectively. The haemoptysis control rates were higher in the technical success group than in the technical failure group (p = 0.029). Conclusions: High haemoptysis control rates for long-term periods were obtained by embolization for all visualized abnormal arteries, regardless of the colonization status, number of bronchiectatic lobes, and target vessels, irrespective of NBSAs.

1 January 2016 in Internal Medicine
Verified
Journal Article
Closed access
KTKeita Takeda
Keita Takeda
NONobuharu Ohshima
Nobuharu Ohshima
HNHideaki Nagai
Hideaki Nagai
RSRyota Sato
Ryota Sato
TATakahiro Ando
Takahiro Ando
KOKen Ohta
Ken Ohta
Mycobacterium shinjukuense lung disease was diagnosed in 3 men and 3 women [mean age: 77.0±12.2 (57-93) years]. On imaging, 3 patients with previous pulmonary tuberculosis exhibited a fibrocavitary pattern, while the other 3 patients showed nodular bronchiectasis. A test with a tuberculosis rRNA identification kit (TRC Rapid(®) M. TB) was falsely positive for M. tuberculosis due to DNA sequence similarity in 16SrRNA. M. shinjukuense was identified by the gene sequences of rpoB, 16S rRNA, and hsp65. The symptoms and imaging findings of most of the patients have improved with chemotherapy with low minimum inhibitory concentrations of anti-tuberculosis drugs.